Lexaria Bioscience Corp. (OTCQX: LXRP) (CNSX: LXX) (the "Company" or "Lexaria") a drug delivery platform innovator, announces it has entered a definitive technology licensing agreement (the "Agreement") with Cannfections Group Inc. whereby Lexaria is providing its patented DehydraTECH™ technology to empower next-generation performance in cannabis infused chocolates and candies to be developed and sold in Canada and internationally.
Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the ''Company'' or ''Lexaria'') announces that, on January 5, 2018, it filed a registration statement and shareholder information circular on Form S-4 with the US Securities and Exchange Commission (the ''SEC'') pursuant to which Lexaria will seek shareholder approval to change its corporate domicile from the State of Nevada to the Province of British Columbia, Canada, home of Lexaria's operations and management.
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX), a drug delivery platform innovator, announces a new topical skin cream research and development program; R&D into nicotine edibles; and updates existing R&D programs.
Topical Skin Formulations for Cannabinoids.
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) a drug delivery platform innovator, announces it has filed a new patent application with the US Patent and Trademark Office utilizing the Lexaria DehydraTECHTM technology for delivery of phosphodiesterase type 5 (PDE5) inhibitors - trade names of existing well-known products include ViagraTM (sildenafil) and CialisTM (tadalafil).
One company we have been watching is Lexaria Bioscience (LXRP) which is levered to the North American cannabis industry. Over the last few months, Lexaria has announced several developments that have the company well positioned for growth throughout 2017.
During the last few months, Lexaria has improved its fundamental story through the following developments:
1) The company was issued several patents around its IP